AstraZeneca has ceased development of its nicotinic channel blocker TC 5214 for which it had collaborated with Targacept as an...
A Phase II asthma study of TC 6987 from Targacept was a double blind, placebo controlled, parallel group trial conducted...
AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with Major Depressive Disorder did not meet...
Targacept has announced top-line results from a Phase IIb clinical trial of TC 5214 as a treatment for Overactive Bladder...
Phase III results of TC 5214, a nicotinic channel blocker from AstraZeneca/Targacept, were disappointing in the first study (RENAISSANCE 3)...
Targacept, Inc. a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, has announced top-line results from a Phase IIb monotherapy clinical...
Targacept Inc., has announced top-line results from a Phase II trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity...
This review discusses the molecular mechanisms associated to the pathogenesis of different types of TC and their clinical relevance.